Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Evaluation of toxicity and response of treatment with carboplatin and docetaxel to patients with epithelial cancer of ovary, fallopian tube or peritoneum with their first relapse occurring at least 6 months after end of first line treatment- Evaluation of toxicity according to Clinical Toxicity Criteria version 2.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Epithelial carcinoma of ovarian, peritoneal or fallopian tube origin.
Female
age above 18 years
WHO performance status 0-2
Life expectancy \> 3 months
Previous treatment with one platinum and taxane containing regimen.
Platinum and taxane sensitive relapse
At least one evaluable/measurable lesion.
Adequate hematologic, renal and liver function
Consent form signed and dated before inclusion
You may not be if
Prior treatment with more than one line of chemotherapy
Concurrent severe and/or uncontrolled co-morbid medical condition.
History of previous or concurrent malignancy within the previous 5 years • History of prior serious allergic reactions such as anaphylactic shock
Pregnant or lactating women (or potentially fertile women not using adequate contraception)
Peripheral neuropathy \> Grade 2
History of allergy to drugs containing the excipient TWEEN 80®.
Concomitant administration of any other experimental drug under investigation or concurrent treatment with any other anti-cancer therapy
Clinical evidence of brain metastases
Clareo Health | A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
